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exogenous insulin administration cannot 
match the exquisite regulation of blood 
glucose (BG) achieved by β-cells within 
the pancreatic islets of Langerhans, where 
endogenous insulin secretion is linked 
through metabolism to glucose transport. 
Poor glucose control results in a high 
risk for diabetes complications, such as 
limb amputation, blindness, and kidney 
failure. In addition, hypoglycemia can 
lead to behavioral and cognitive distur-
bance, seizure, coma, brain damage, or 
death. “Smart” glucose-responsive insulin 
delivery devices or formulations, which 
can mimic the function of β-cells to reg-
ulate insulin “secretion,” are therefore 
highly desirable with an aim to improve 
blood glucose control and quality of life 
for people with diabetes.[5,6]
Such smart therapies generally integrate a glucose-sensing 
or conversion module and a sensing/conversion-activated 
insulin releasing module. For example, the wearable closed-
loop electronic/mechanical pumps combine a continuous glu-
cose-monitoring electrochemical sensor and an external insulin 
infusion pump.[4] These systems have historically been limited 
by lag in blood glucose equilibration with the interstitium, 
insulin absorption into the circulation and biofouling.[7] Syn-
thetic materials-based glucose-responsive formulations have 
also been widely explored since the 1970s.[5,8–10] Three clas-
sical strategies are often utilized,[6] typically including dif-
ferent glucose-sensing moieties: glucose oxidase,[11–15] glucose-
binding proteins (e.g., ConA),[16] and phenylboronic acid[17] for 
achieving glucose triggers. A variety of formulations, such as 
bulk hydrogels, microgels, emulsion-based nanoparticles, and 
self-assembled vesicles have been developed to respond toward 
a hyperglycemic state to swell,[18,19] shrink,[20] degrade,[11,14] or 
dissociate[13,21,22] in order to promote the release of insulin. 
In spite of these promising strategies, it remains challenging 
to demonstrate a system that responds rapidly to elevated BG 
levels, closely mirroring the kinetics of a healthy pancreas. In 
addition, immunological responses, stability in the physiolog-
ical environment and long-term toxicity of those synthetic sys-
tems require further investigation.
Here we report a new strategy for glucose-responsive 
insulin delivery based on the red blood cells (RBCs) or eryth-
rocytes system. As illustrated in Figure 1, we found that the 
glucose derivative-modified insulin (designated Glc-Insulin) 
can effectively bind to the membrane of mouse and human 
RBCs. We think this occurs maybe via the glucose transporter 
(GLUT) molecule, an abundant membrane protein on RBCs. 
Such binding is reversible and insulin can be rapidly released 
Glucose-responsive delivery of insulin mimicking the function of pancreatic 
β-cells to achieve meticulous control of blood glucose (BG) would revolu-
tionize diabetes care. Here the authors report the development of a new 
glucose-responsive insulin delivery system based on the potential interaction 
between the glucose derivative-modified insulin (Glc-Insulin) and glucose 
transporters on erythrocytes (or red blood cells, RBCs) membrane. After being 
conjugated with the glucosamine, insulin can efficiently bind to RBC mem-
branes. The binding is reversible in the setting of hyperglycemia, resulting in 
fast release of insulin and subsequent drop of BG level in vivo. The delivery 
vehicle can be further simplified utilizing injectable polymeric nanocarriers 
coated with RBC membrane and loaded with Glc-Insulin. The described work 
is the first demonstration of utilizing RBC membrane to achieve smart insulin 
delivery with fast responsiveness.
Diabetes currently affects 415 million people worldwide and 
this number is expected to increase to 642 million by 2040.[1,2] 
Insulin is essential for survival in type 1 diabetes and often 
required for treatment of type 2 diabetes in order to control 
glycemia and prevent complications.[3,4] However, traditional 
from RBCs under high glucose conditions, mediated by dis-
placement due to competitive interaction of free glucose with 
GLUTs. As the most abundant cellular constituent in the blood, 
human RBCs have a life span of 100–120 days as natural car-
riers for oxygen in blood vessel. Importantly, inherent biocom-
patibility of RBCs makes them excellent candidates for robust 
glucose-response insulin delivery carriers.[23–29] Using chemi-
cally induced type 1 mice as an animal model, we demonstrated 
that intravenous (i.v.) injection of mouse RBCs (mRBCs) cou-
pled with Glc-Insulin greatly prolonged the therapeutic effect of 
insulin to maintain BG levels within the normal range.
Furthermore, this “glucose-responsive RBC” strategy can 
be extended by combining poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles coated with RBC membranes (RM@PLGA). As 
with intact RBCs, Glc-Insulin can binds to RM@PLGA nano-
particles specifically. Insulin release from these nanoparticles 
is self-regulated in a BG-mediated manner. To our best knowl-
edge, the described work is the first demonstration of utilizing 
RBCs membrane to realize glucose-responsive insulin delivery 
both in vitro and in vivo.
Glucosamine was conjugated to insulin to from Glc-Insulin 
via a bifunctional maleimide linker (Figure S1, Supporting 
Information). Many published studies have demonstrated 
that using glucose conjugates for targeting the GLUTs of 
cells.[30–36] In our work, Glc-Insulin is clearly identified by the 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and 
matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-MS) (Figure S2, Supporting Information). As cal-
culated by MALDI-MS, two glucose derivative molecules are 
conjugated to each insulin molecule. The circular dichroism 
spectra of native insulin and Glc-Insulin are virtually super-
imposable, indicating that the secondary structures of these 
species are similar if not identical (Figure S3A, Supporting 
Information). Most importantly, the Glc-Insulin conjugate 
and native insulin do not display any significant difference in 
their bioactivity profiles upon administration in streptozotocin 
(STZ)-induced type 1 diabetic mice (Figure S3B, Supporting 
Information). In short, the modification of insulin with glucose 
derivative has a statistically insignificant impact on bioactivity 
relative to unmodified insulin.
GLUTs are membrane proteins that facilitate the transport 
of glucose down a concentration gradient through the plasma 
membrane.[37] Glucose transporter 1 (GLUT1) is the main glu-
cose transporter on human RBCs; while glucose transporter 
4 (GLUT4) is the dominant glucose transporter in RBCs of adult 
mice[38–40] (Figure S4, Supporting Information). Meanwhile, 
glucosamine is structurally homologous to glucose and has 
also been shown to bind to GLUT1/GLUT4 transporters.[41,42] 
The affinity for glucosamine and glucose of GLUT1 and 
GLUT4 are similar.[43,44] In our study, we hypothesize that 
Glc-Insulin can bind to mRBCs via the specific glucosamine-
GLUT binding. The mRBCs were incubated with Glc-Insulin 
overnight and imaged using the confocal fluorescence micro-
scope. Indeed, we observed effective binding of Glc-Insulin to 
Figure 1. Schematic of the glucose-responsive insulin delivery system based on red blood cells. Synthesized Glc-Insulin was attached to erythrocytes 
by interacting with glucose receptor/transporter on plasma membranes. I,II) Collection and isolation of mRBCs. III) Binding of Glc-Insulin to mRBCs.
mRBCs (Figure 2A). Importantly, this binding of Glc-insulin 
toward RBCs can be significantly inhibited by D-glucose and 
Cytochalasin B,[35] suggesting the GLUT-mediated interaction 
(Figure 2B). We further compared the Glc-Insulin with native 
insulin. The flow-cytometry results suggested that the attach-
ment of Glc-Insulin toward mRBCs was via the specific inter-
action. With modification of the glucose derivative, insulin 
more easily attached to mRBCs than native insulin (Figure 2C). 
While insignificant binding of free insulin toward mRBCs 
was observed (Figure 2D). The loaded insulin to mRBCs was 
determined by the enzyme-linked immunosorbent assay 
(ELISA). mRBCs could be readily coupled with Glc-Insulin about 
5 × 10−16 g per cell. Furthermore, the annexin V binding 
assay confirmed that insulin binding did not cause significant 
damage to mRBCs (Figure S5, Supporting Information).
To examine the glucose-responsive insulin release perfor-
mance, Glc-Insulin attached mRBCs were incubated in phos-
phate-buffered saline (PBS) containing different concentrations 
of glucose. Rat anti-human insulin fluorescein isothiocyanate 
(FITC)-conjugated antibody was used to label the bound 
Figure 2. Characterization of the Glc-Insulin attached mRBCs. A) Confocal immunofluorescence imaging of the Glc-Insulin attached to mRBCs. 
Rat anti-human insulin FITC-conjugated antibody was used to detect insulin on mRBCs (scale bar = 10 µm). B) Flow cytometry analysis of mRBCs 
incubated with different experimental settings. The binding of glucose-insulin and RBCs was significantly inhibited by D-glucose and Cytochalasin B. 
C) Flow cytometry data of mRBCs incubated with insulin and Glc-insulin. D) Flow cytometric assay used to assess the specific binding of Glc-Insulin
toward mRBCs. E) Confocal microscopy images of the Glc-Insulin attached mRBCs untreated and treated with 400 mg dL−1 glucose solution (scale
bar = 50 µm). F,G) Flow cytometry data of insulin attached mRBCs treated with different concentration of glucose solutions and corresponding mean
fluorescent intensity (MFI) quantification of insulin-mRBCs (Ctr means naïve mRBCs). H–J) In vitro glucose-responsive insulin release. H) In vitro
accumulated Glc-Insulin release from the mRBCs in several glucose concentrations as indicate at 37 °C. I) In vitro accumulated Glc-Insulin release
from the mRBCs. The arrow indicates the glucose (400 mg mL−1) administration points. J) Pulsatile release profile of mRBCs presents the rate of
insulin release as a function of glucose concentration (blue: 100 mg dL−1 and red: 400 mg dL−1). The error bars are based on the standard deviation
(SD) of triplicated samples.
insulin. As observed in confocal imaging (Figure 2E), com-
pared to untreated insulin-mRBCs, the fluorescence signals of 
insulin on the mRBCs membrane were notably decreased after 
30 min when treated with 400 mg dL−1 glucose in PBS, due to 
the detachment of the insulin from mRBCs (Figure 2E). The 
flow-cytometry results further substantiated that the signals of 
insulin on mRBCs decreased with increased glucose concentra-
tion. Only ≈50% less insulin signals was detected on 400 mg dL−1 
glucose treated mRBCs (Figure 2F,G). We next assessed the 
insulin release profile in response to varying glucose levels, 
including a typical hyperglycemic level (400 mg dL−1), nor-
moglycemic levels (100 and 200 mg dL−1), and a control level 
(0 mg dL−1). The released amounts of insulin from mRBCs 
were determined by the ELISA assay. As shown in Figure 2H, 
about 50% of insulin was released from mRBCs incubated with 
400 mg dL−1 glucose within 2 h, significantly higher than sam-
ples associated with normal glucose levels. These results were 
also consistent with the flow cytometry data mentioned above. 
Importantly, the quick release of insulin after exposure to high 
glucose was documented (Figure 2I), suggesting the potential 
for clinical effectiveness. Furthermore, pulsatile release kinetics 
of insulin was achieved when the glucose concentration was 
periodically varied between the normal and hyperglycemic 
levels for several cycles (Figure 2J). The release rates increased 
to a maximum within the first 10 min and then gradually 
decreased, which can be attributed to the gradual depletion of 
Glc-Insulin interacting with GLUTs.
Next, we examined the glucose-responsive performance of Glc-
Insulin conjugated mRBCs (insulin-mRBCs) in vivo. To assess 
the blood-circulation behavior of the cell carrier, mRBCs coupled 
with FITC were loaded with Glc-Insulin and then i.v. injected 
into healthy mice. About 3 µL of blood was extracted from the 
tail at different time points and then dispersed in 0.5 mL PBS 
with anticoagulants. Flow cytometry measurement was applied 
to determine the percentage of insulin-mRBC (positive in FITC) 
in the blood samples. The percentage of mRBC (injected) among 
total collected mRBCs appeared to be stable even 72 h after 
injection, suggesting the excellent stability of insulin-mRBCs 
(Figure S6A,B, Supporting Information). Liver is one of major 
target tissues of insulin.[45] The liver tissues of mice treated with 
insulin-mRBCs or free insulin were further collected for com-
parison of immunofluorescence imaging. The fluorescence sig-
nals of insulin can be detected up to 4 d in liver after insulin-
mRBCs treatment; while for the mice treated with free insulin, 
little signal can be found at 24 h after injection (Figure S6C, Sup-
porting Information). This result further substantiated the long-
term insulin delivery efficiency by this RBCs system.
We then assessed the efficacy of insulin-mRBCs for treatment 
of hyperglycemia in STZ-induced type 1 diabetic mice. Groups 
of animals were treated by i.v. injection with insulin-mRBCs, 
free insulin plus mRBCs, Glc-Insulin alone, and PBS control. 
The BG levels of treated mice were then monitored over time. 
As shown in Figure 3A, for mice treated with free insulin plus 
mRBCs and with Glc-Insulin, the BG levels declined steadily to 
hypoglycemic within 1 h and recovered to hyperglycemic range 
(≈500 mg dL−1) quickly within 24 h. In contrast, the BG level 
in mice treated with insulin-mRBCs decreased and maintained 
at about 200 mg dL−1 at least 24 h and increased gradually over 
4 d. We attributed this remarkably longer lasting impact to the 
stability of the mRBCs carriers in the circulation with sustained 
glucose-dependent insulin release.
To further understand the dynamics of insulin release in 
vivo, we performed intraperitoneal glucose tolerance tests 
(IPGTT) 1.5 h after administration of the insulin-mRBCs 
(Figure 3B). As shown, following the IPGTT, the control 
healthy mice exhibited a quick increase in BG level and 
recovery to a normal BG level within 2 h. In diabetic mice, BG 
levels of insulin-mRBCs treated mice show a delayed increase 
in BG level, then decline to ≈200 mg dL−1 and maintained a 
normoglycemic state within 2 h. In STZ-diabetic mice treated 
with free insulin + mRBCs or with Glc-Insulin, BG levels 
only exhibited a fleeting response. To quantitate the glucose 
response to the various insulin formulations,[15,17] the area 
under the curve was calculated for each group. Insulin-mRBCs 
treated mice show enhanced responsiveness to IPGTT as com-
pared to free insulin treated mice (Figure 3C). Furthermore, 
plasma insulin levels of diabetic mice were monitored over 
time by ELISA after IPGTT (Figure 3D). Very importantly, as 
BG levels increased, the serum insulin level followed closely 
both in the rise of glucose and on its fall to normal. This in 
vivo demonstration of glucose-responsive release of insulin is 
extremely challenging and remains elusive for most glucose-
responsive systems. Plasma glucagon levels of healthy mice, 
STZ-mice, and STZ-mice treated with RBC-Insulin 2 h were 
also investigated. STZ-mice had a threefold increase plasma 
glucagon levels compared with the nondiabetic controls, 
whereas RBC-Insulin treated mice had plasma glucagon levels 
that were similar to the nondiabetic controls (Figure S7, Sup-
porting Information). Moreover, we compared young (from 
4 weeks old mice) and old (from 1 year old mice) red blood 
cell vehicles for insulin delivery as well (Figure S8, Supporting 
Information). Interestingly, we found that mRBCs from young 
mice had a more effective and longer antidiabetes efficacy than 
mRBCs from old mice. This result may be attributed to the 
more stable and longer life span of mRBCs from young mice 
than mRBCs from aged mice in circulation.[46,47]
To assess the potential for insulin-mRBCs to induce hypo-
glycemia, we studied their effect in healthy mice under normo-
glycemic conditions (Figure 3E). The native insulin + mRBCs 
and Glc-Insulin treated mice showed significantly decreased 
BG levels compared to insulin-mRBCs treated mice. The corre-
sponding hypoglycemia index was calculated to assess the risk 
of hypoglycemia.[15,17] Treated with insulin-mRBCs significantly 
reduced hypoglycemic index compared to the control groups 
(Figure 3F).
Compared with the mouse erythrocyte, the human erythro-
cyte is the cell type expressing the highest level of the GLUT1, 
owning 500 000–700 000 molecules per cell.[38,48] Therefore, 
hRBCs may have even better insulin delivery capability than 
mRBCs. To test this hypothesis, we examined insulin loading 
capacity of hRBCs. Nearly 60% of Glc-Insulin was attached 
to the hRBCs membrane while only 20% of Glc-Insulin was 
detected on mRBCs (Figure S9, Supporting Information). Fur-
thermore, glucose-responsive insulin release from hRBCs was 
validated as well (Figure S9, Supporting Information). Of note, 
the human erythrocytes only have 2000 insulin binding sites 
per erythrocyte,[49] resulting in the negligible binding amount 
of free insulin toward hRBCs.
In addition to naïve RBCs, we also synthesized a biomimetic 
nanoformulation using the RBC membrane-coated nanopar-
ticles for “smart” insulin delivery in vitro and in vivo. PLGA 
nanoparticles coated with RBC membranes (RM) were fabri-
cated according to the reported method (Figure 4A).[50] The 
obtained RM@PLGA nanoparticles were monodispersed as 
revealed by the transmission electron microscopy (TEM) and 
dynamic light scattering (DLS). The TEM images show that 
most of PLGA NPs are well coated with RBC membranes with 
a diameter of 100 nm (Figure 4B). After RM coating, PLGA 
NPs display a slight increase in the DLS measured diam-
eter from 145 to 160 nm (Figure 4C and Figure S10, Sup-
porting Information). Western blot analysis was conducted to 
verify that GLUTs are present on the RM coated PLGA NPs 
(Figure 4D). Next, Glc-Insulin was attached to RM@PLGA 
NPs via the specific glucosamine-GLUT interaction as well. 
The attachment was also confirmed by confocal imaging and 
an ELISA assay (Figure S11, Supporting Information). As 
expected, PLGA@RM nanocarriers also release insulin in a 
glucose-responsive manner (Figure 4E). Further in vivo studies 
demonstrated that, compared with free insulin + RM@PLGA 
NPs, insulin-RM@PLGA NPs greatly prolongs the insulin 
effect to maintain BG levels and reduces the risk of hypogly-
cemia after injection (Figure 4F–H and Figure S12, Supporting 
Information).
Development of glucose-responsive formulations for insulin 
delivery has received considerable attentions.[51] However, it is 
extremely challenging to realize a combination of fast response, 
long-term persistence, and excellent biocompatibility. This 
report demonstrates an innovative strategy using “glucose-
responsive cell” integrated with modified insulin. Unlike most 
existing smart insulin delivery systems that are applying syn-
thetic materials, the formulation demonstrated in this study is 
simply generated by integration of RBCs and glucose derivative- 
modified insulin. In addition, the binding competition between 
glucose and glucose derivative-modified insulin bound to facili-
tative GLUTs offers a new and simple strategy for glucose-
responsive insulin release with fast responsiveness. We dem-
onstrated the reversible binding between glucose derivative-
modified insulin and glucose transporters activates rapidly, 
which enables the release of insulin from the cellular carriers 
to be extremely fast. The glucose-response release of insulin 
from the RBCs was also clearly validated through the glucose 
tolerance test in vivo. In the further step, this approach could 
be simply integrated with a painless microneedle-array patch 
for improving the quality of life of diabetic patients. Lastly, this 
strategy can be further extended to patient-centered cell therapy 
with therapeutics for treating a variety of diseases, with merits 
of both long-term sustained release and physiological signal-
mediated controlled release.
Figure 3. In vivo insulin delivery by insulin-mRBCs. A) BG levels in STZ-induced diabetic mice after treatment with free insulin + mRBCs, Glc-Insulin, 
insulin-mRBCs, and PBS control. The arrow indicates the administration time. B) In vivo glucose tolerance test in STZ-diabetic mice or nondiabetic 
mice. With the insulin-mRBCs i.v. injected at time 0 and an IPGTT performed 1.5 h following insulin administration. The arrow indicates the admin-
istration point. C) The responsiveness was calculated based on the area under the curve from 90 to 200 min, with the baseline set at the 90 min BG 
reading. D) Change in plasma insulin levels and glucose levels after IPGTT. The arrow indicates the administration point. E) BG changes of healthy 
mice administered by insulin-mRBCs over time. The arrow indicates the administration point. F) Quantification of the hypoglycemia index, calculated 
from the difference between the initial and nadir BG readings divided by the time at which nadir was reached. The error bars are based on the SD of 
five mice per group (P-values: *P < 0.05).
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Figure 4. Glucose-responsive insulin delivery by injectable RBC-mimicking nanoparticles. A) Schematic of fabrication of insulin-PLGA@RM 
nanoparticles. I) Isolation of RBC membranes. II) Coating RM to PLGA nanoparticles. III) Binding of Glu-Insulun to PLGA@RM nanoparticles. 
B) TEM images of PLGA@RM nanoparticles. Inset: Zoom-in image (scale bar = 200 nm). C) Dynamic light scattering (DLS) characterization of
PLGA@RM nanoparticles. D) Western blot was conducted to verify that GLUT4 existed on the RM coated PLGA NPs. E) In vitro accumulated
insulin release from the PLGA@RM in several glucose concentrations as indicated at 37 °C. F) In vivo BG levels in STZ-induced diabetic mice
after treatment with free insulin + PLGA@RM NPs, insulin-PLGA@RM NPs, and PBS control. The arrow indicates the administration point. 
G) In vivo glucose tolerance test toward diabetic mice. With the insulin-PLGA@RM nanoparticles i.v. injected at time 0 and an IPGTT performed
1.5 h following insulin administration. The arrow indicates the administration point. H) Responsiveness was calculated based on the area under
the curve (AUC) in 120 min, with the baseline set at the 90 min BG reading. The error bars are based on the standard deviation (SD) of five mice
per group (P-values: *P < 0.05).
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